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AntidepressantThe relationship between Alzheimer's disease (AD) and depression has been well established in terms of epide-
miological and clinical observations. Depression has been considered to be both a symptom and risk factor of AD.
Several genetic and neurobiological mechanisms have been described to underlie these two disorders. Despite
the accumulating knowledge on this topic, the precise neuropathological mechanisms remain to be elucidated.
In this study,we propose that synaptic degeneration plays an important role in the disease progression of depres-
sion and AD. Using primary culture of hippocampal neurons treated with oligomeric Aβ and corticosterone as
model agents for AD and depression, respectively, we found signiﬁcant changes in the pre-synaptic vesicle pro-
teins synaptophysin and synaptotagmin.We further investigatedwhether the observed protein changes affected
synaptic functions. By using FM®4-64 ﬂuorescent probe, we showed that synaptic functions were compromised
in treated neurons. Our ﬁndings led us to investigate the involvement of protein degradation mechanisms in
mediating the observed synaptic protein abnormalities, namely, the ubiquitin–proteasome system and autoph-
agy. We found up-regulation of ubiquitin-mediated protein degradation, and the preferential signaling for the
autophagic–lysosomal degradation pathway. Lastly, we investigated the neuroprotective role of different classes
of antidepressants. Our ﬁndings demonstrated that the antidepressants Imipramine and Escitalopramwere able
to rescue the observed synaptic protein damage. In conclusion, our study shows that synaptic degeneration is an
important common denominator underlying depression and AD, and alleviation of this pathology by
antidepressants may be therapeutically beneﬁcial.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is characterized by progressive degenera-
tion of the brain and its functions. As a result, AD patients present
withmemory deﬁcits, cognitive decline, and diverse behavioral changes
[1]. Neuropsychiatric symptoms are observed throughout the course ofoid; CORT, corticosterone; E1,
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ights reserved.AD. They occur along the progression of disease and may even occur
prior to signiﬁcant decline in cognitive function [2]. Such symptoms
include depression, apathy, agitation, and hallucinations. Combined
with cognitive deterioration, these symptoms compound patient dis-
ability and caregiver burden [3].
AD is represented by two pathological hallmarks, namely β-amyloid
(Aβ) plaques and neuroﬁbrillary tangles (NFTs). Studies have shown
that abnormally folded Aβ and tau proteins trigger cascades of neurode-
generative processes, including dysregulation of cholinergic neurons,
synaptic degeneration, neuroinﬂammation, autophagy, and apoptosis
[1].
Depression is one of the neuropsychiatric symptoms frequently
observed in AD. It is characterized by prolonged period of low mood,
anhedonia, and changes in sleep and appetite. Prevalence of depression
in AD patients ranges from 20 to 50%. Studies have also shown that
depressive symptoms may precede cognitive decline [3,4].
A number of risk factors for depression in AD patients have been
identiﬁed: family history of mood disorder in ﬁrst-degree relatives,
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history of depression itself has also been associated with increased risks
of developing AD, especially among elderly women [5,7]. Several genet-
ic risk factors have been identiﬁed to inﬂuence the development of
depression and AD, including brain-derived neurotrophic factor genetic
variation and being heterozygous for promoter region of interleukin-1β
[8,9].
Several neurobiological mechanisms have been found to cause
cellular damage leading to depression. They include hypothalamic–
pituitary–adrenal (HPA) axis dysfunction, monoamine deﬁciency,
neuroinﬂammation, and neuroplastic changes [10]. HPA axis dys-
function appears to be responsible for a great extent of the abnormalities
observed in depression. HPA axis dysfunction results in prolonged re-
lease of the stress hormone, cortisol, which has been found to be elevated
in depressedpatients [11]. Cortisol binds tomembranemineralocorticoid
and glucocorticoid receptors which allow for rapidmodulation of synap-
tic transmission in the brain [12]. The hippocampus is of particular
importance because it is rich in corticosteroid receptors, and structural
changes in this brain region have been observed in depressed patients
[13].
In the case of AD, high levels of corticotropin-releasing hormone and
cortisol, secondary toHPA axis deregulation, have been found to increase
the risk and rate of disease progression [14]. Adrenocortical hyperactivity
was found to be associatedwith increased Aβ plaque deposition and NFT
formation in an animal model of AD [15]. Furthermore, cholinergic dys-
function found inADhas been shown to suppress glucocorticoid receptor
feedback regulation of the HPA axis [16]. Prolonged release of cortisol
and HPA axis activation is detrimental to the glucocorticoid-rich hippo-
campus, which is one of the earliest areas to be affected in AD [17].
It appears that the pathophysiological mechanisms underlying
depression are common in AD. For instance, dysregulation of neuro-
transmitter systems, neuroinﬂammation and changes in neuroplasticity
have been observed in both disorders. Studies are beginning to demon-
strate the role of such mechanisms linking depression and AD [18,19].
We are particularly interested in neuroplastic changes at the synapse,
as they are sites of neuronal communication that are essential for prop-
er brain functions including learning and memory [20].
In AD, altered expressions of synaptic proteins were found to occur
early in the disease processes and synaptic degeneration was found
to correlate best with cognitive decline [21–23]. Aβ has been shown to
impair synaptic functions and spine structure in animal models of AD
[24]. Furthermore, reduction of pre-synaptic vesicle proteins such as
synaptophysin has been consistently observed in transgenic AD mouse
models [25–27]. In conjunction with loss of pre-synaptic proteins, loss
in post-synaptic proteins such as post-synaptic density 95 (PSD95)
and glutamate receptor subunit GluR1 has also been demonstrated
[28–30].
Synaptic disturbances have also been shown to be involved in sever-
al psychiatric disorders, including autism, schizophrenia and bipolar
disorder [20,31]. Evidence suggests altered synaptic structure and func-
tions in depression as well. Loss of hippocampal volume due to reduced
neurogenesis has been observed in depressed patients [32,33]. Reduc-
tions in both neurogenesis and synaptophysin levels have been shown
in a chronic unpredictable mild stress rat model of depression [34]. In
another stressed rat model of depression, dendritic spine loss was
observed [35]. Furthermore, over-expression of pre-synaptic protein,
piccolo, was found to induce depressive-like behavior in mice [36].
These studies provide evidence that stress is involved in altered synap-
tic functions, which in turn leads to the development of depression.
Several mechanisms are involved in the disruption of synaptic func-
tions. They include alterations in brain-derived neurotrophic factor
(BDNF) and disrupted synaptic signaling pathways responsible for syn-
aptic maturation, impaired synaptic mitochondrial dynamics, and oxi-
dative stress induced variations in synaptic genes [37–39].
Taking into consideration the importance of synapses inmaintaining
proper brain function and the role of its dysfunction in psychiatricdisorders, we hypothesize that synaptic degeneration could be a com-
mon link between depression and AD. Since various classes of antide-
pressants have been the mainstay of depression pharmacotherapy, we
also hypothesize that they will be able to ameliorate signs of synaptic
damage. This will provide a platform for future drug development to
prevent synaptic degeneration in the treatment of depression in AD.2. Materials and methods
2.1. Cell culture models
Primary culture of hippocampal neurons was used in this study
(Supplementary Materials and methods). The hippocampal area was
chosen because it is one of the affected areas in both depression and
AD. The hippocampus plays important roles in memory consolidation
and is one of the earliest affected areas in AD brains [40]. Moreover,
the hippocampus contains a large number of glucocorticoid receptors,
making it prone to chronic stress, which is highly implicated in depres-
sion [41]. Lastly, reduction in hippocampal volume has been observed in
both disorders [33,42].
Oligomeric Aβ1-42 was used as a model agent to represent AD
pathologies. Corticosterone (CORT), a rodent derivative of cortisol, was
used as a model agent for depression. Both chemicals were used at a
sub-lethal dosage to simulate early disease events.
Oligomeric Aβ was reconstituted in anhydrous dimethyl sulfoxide
(DMSO) (Supplementary Materials and methods) and CORT (Sigma-
Aldrich, St. Louis, MO, USA) was reconstituted in 100% ethanol. Both
agents were diluted in culture medium to the desired concentration
for treatment. The same concentration of anhydrous DMSO or 100%
ethanol was diluted in culture medium as control.
To investigate the neuroprotective effects of antidepressants,
neurons were pre-treated with Imipramine (Sigma-Aldrich) and
Escitalopram (Lundbeck, Copenhagen, Denmark) for 1 h, and incubated
in either oligomeric Aβ or CORT for 24 h. Imipramine and Escitalopram
were dissolved inmilli-Qwater and further diluted in culturemedium to
the desired concentration for treatment.2.2. Immunocytochemistry
For immunocytochemical staining, primary hippocampal neurons
cultured on coverslips (Thermo Scientiﬁc) were ﬁxed with 4% parafor-
maldehyde (PFA) for 20 min, permeabilized with 0.1% Triton X-100 in
TBS for 7 min, and blockedwith 10% bovine serumalbumin for 1 h. Incu-
bation of primary antibody was done for 1 h at room temperature at
1:400 dilution for the following antibodies: synaptophysin (Chemicon,
Temecula, CA, USA) and synaptotagmin (Calbiochem, La Jolla, CA, USA).
Ubiquitin-48 (Millipore, Billerica, MA, USA), ubiquitin-63 (Millipore),
and LC3-II (MBL International, Woburn, MA, USA) were incubated over-
night at 4 °C at 1:400. Neurons were then incubated with secondary an-
tibody (anti-rabbit or mouse, Alexa-ﬂuor 488 or 568, 1:400, Molecular
Probes, Eugene, OR, USA) and mounted on microscope slides (Thermo
Fisher Scientiﬁc, Waltham, MA, USA) using ProLong® Gold antifade
mounting medium (Invitrogen) and imaged using the LSM510-meta
laser scanning confocal microscope (Carl Zeiss, Oberkochen, Germany).
Images were analyzed using MacBiophotonics ImageJ (http://rsb.info.
nih.gov/ij/).2.3. Transduction
Neurons cultured onMatTek disheswere transducedwith 10 particles
per cell of CellLight® synaptophysin-GFP (Invitrogen) overnight, prior to
treatment. After treatment, neurons were imaged using the LSM510 con-
focal microscope. Images were then analyzed using MacBiophotonics
ImageJ.
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Five micromolars of FM®4-64 (Invitrogen) ﬂuorescent probe was
added to hippocampal neurons cultured on coverslips. The neurons
were stimulated with 100 mM potassium chloride for 3 min to induce
endocytosis. They were then washed with HBSS and incubated in the
dye for 30 min at 37 °C and 5% CO2 for complete endocytosis. One
group was ﬁxed with 4% PFA for 20 min. The remaining neurons were
then washed and stimulated again with 100 mM potassium chloride
for 10 min to induce exocytosis. The second group of neurons was
then ﬁxed with 4% PFA for 20 min. The coverslips were mounted on
microscope slides using ProLong® Gold antifade mounting medium
(Invitrogen), analyzed using the LSM510 confocal microscope and
quantiﬁed using MacBiophotonics ImageJ.
2.5. Western blot analysis
Total cell lysate was extracted by ice-cold lysis buffer containing
10 mM Tris (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM
NaF, 20 mM Na4P2O7, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5%
deoxycholate, phenylmethylsulfonylﬂuoride (1 mM), protease inhibitor
cocktail and phosphatase inhibitor cocktail. The lysate was then sonicat-
ed, centrifuged at 14,000 rpm for 30 min at 4 °C, and the supernatant
was collected for analysis. Protein concentration was measured as
directed in the protein assay kit (Bio-Rad, Hercules, CA, USA). Protein
extracts were separated by SDS-PAGE gel and transferred onto PVDF
membrane (Bio-Rad). The membrane was blocked with 5% non-fat milk
(Bio-Rad) overnight. Primary antibodies for synaptophysin (Abcam) and
synaptotagmin (Abcam) were incubated for 4 h at 1:2000 dilutions and
β-actin (Sigma) were incubated for 1 h at 1:5000. Western blots were
subsequently incubatedwith horseradish peroxidase-conjugated second-
ary antibody for 45 min. Bands were visualized on Biomax X-ray ﬁlm
using ECL spray (Upstate). Bandswere quantiﬁed usingMacBiophotonics
ImageJ.
2.6. Proteasome activity assay
Total cell lysate was harvested with ice cold lysis buffer containing
20 mM Tris, pH 7.2, 1 mM EDTA, 1 mMNaN3, 1 mM DTT, and protease
inhibitor cocktail on ice and centrifuged for 10 min at 20,000 g. Super-
natants were quantiﬁed in triplicate in black OptiPlate™ 96 well plates
(Perkin Elmer, Waltham, USA). Background proteolytic activity was
controlled for by incubation of duplicate samples with 20 μM
MG132 (Boston Biochem, Cambridge, MA, USA) prior to incubation
with ﬂuorogenic substrates. N-succinyl-Leu-Leu-Val-Tyr-7-amido-
4-methylcoumarin (Suc-LLVY-AMC) (Enzo Life Sciences, Farmingdale,
USA) for chymotrypsin-like activity, butoxycarbonyl-Leu-Arg-
Arg-amido-4-methylcoumarin (Boc-LRR-AMC) (Enzo Life Sciences) for
trypsin-like activity, and benzyloxycarbonyl-Leu-Leu-Glu-amido-4-
methylcoumarin (Z-LLE-AMC) (Enzo Life Sciences) for caspase-like
activitywere incubatedwith samples at 20 μMfor 45 min at 37 °C. Fluo-
rescence was read on a microplate reader (Perkin Elmer) at 390 nm
excitation and 460 nm emission. Fluorescence activity of all three
proteasome proteolytic sites was taken as the level of ﬂuorescencemea-
sured after subtraction from background.
2.7. Statistical analysis
Statistical comparison between two groups was determined by
unpaired t-test. Data for multiple variable comparisons were analyzed
by one-way analysis of variance (ANOVA). For the comparison of signif-
icance, Tukey's test was used as a post hoc test. The statistical program
used was GraphPad Prism (GraphPad Software, La Jolla, CA, USA).
Results were expressed as mean ± standard error (SE) from at least
three independent experiments.3. Results
3.1. Oligomeric Aβ and CORT caused pre-synaptic damage
To investigate the effects of low-dose oligomeric Aβ andCORTon the
pre-synaptic site, hippocampal neuronswere treatedwith oligomeric Aβ
or CORT at 0.5 μM for 24 h and immunocytochemical analyses were
performed for synaptophysin and synaptotagmin. Primary hippocampal
neurons were also transduced with CellLight® synaptophysin-GFP for
live-cell imaging. The number of immunoreactive positive puncta of
synaptophysin and synaptotagmin was reduced after 24 h of Aβ treat-
ment (Fig. 1A–E). Aggregation of synaptophysin and synaptotagmin
was observed after treatment with 0.5 μM Aβ for 12 h (Fig. 1A, F & G).
Protein expression of synaptophysin and synaptotagmin was reduced
with 0.5 and 5 μM Aβ treatments by Western blot analysis (Fig. 1H–J).
CORT induced aggregation of the synaptic proteins (Fig. 2A–D), without
affecting the total protein expression level (Fig. 2E & F).
3.2. Oligomeric Aβ and CORT compromised synaptic functions
To investigate whether the observed pathological changes affected
synaptic functions, we employed the FM®4-64 ﬂuorescent probe,
which is commonly used to examine endocytosis and exocytosis. Endo-
cytosis is monitored by dye uptake and the subsequent increase in
ﬂuorescent intensity. Exocytosis is examined by dye release and the sub-
sequent decrease in ﬂuorescent intensity. Images shown in the ﬁgure
represent dye uptake and release speciﬁcally at theneuritis (Fig. 3). Olig-
omeric Aβ and CORT treatments at 0.5 μM showed similar ﬂuorescent
intensities compared to control during dye uptake, indicating that endo-
cytosis was unaffected (Fig. 3A & B). However, during exocytosis when
the dye was supposed to be released (and the subsequent decrease in
ﬂuorescent intensity), the ﬂuorescent intensity of the treated neurons
remained at a high level (Fig. 3A & C), suggesting an impairment in
exocytosis following oligomeric Aβ and CORT treatments.
3.3. Involvement of protein degradation mechanisms at the synapse
Since our results showed loss and aggregations of synaptic protein,
we further investigated the mechanisms underlying the clearance of
aggregated synaptic proteins. We found that oligomeric Aβ and CORT
at 0.5 μM inﬂuenced ubiquitin-mediated protein degradation mecha-
nisms, indicated by the increase in the immunoreactivity of ubiquitin-
48 and ubiquitin-63 (Fig. 4A & B, D & E). Ubiquitin-63 was found to sig-
niﬁcantly co-localize with synaptophysin (Fig. 4D & F). On the other
hand, ubiquitin-48 was found in close proximity to synaptophysin, but
did not signiﬁcantly co-localize (Fig. 4A & C). Lactacystin, a proteasome
inhibitor, served as a positive control for ubiquitin accumulation.
3.4. Corticosterone and oligomeric Aβ did not affect proteasome activity
Since oligomeric Aβ and CORT were found to induce an increased
co-localization between synaptophysin with ubiquitin-63 but not
with ubiquitin-48, the ubiquitin–proteasome pathway may not be the
major pathway or mechanism being affected in oligomeric Aβ- and
CORT-treated cells. Therefore, we went on to examine whether oligo-
meric Aβ and CORT treatments affect proteasome activity within our
model. Our results found no signiﬁcant changes in the chymotrypsin-
like, trypsin-like and caspase-like activity of the proteasome in both
treatment groups (Fig. 5).
3.5. Antidepressants were able to alleviate pathological changes of
pre-synaptic proteins
Antidepressants that target the monoaminergic system have long
been used in the treatment of major depressive disorder. Therefore,
we investigated if they could alleviate the pre-synaptic damage exerted
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treatment with 10 μM Imipramine or Escitalopram for 1 h was able
to rescue the observed synaptic pathologies (Fig. 6). For oligomeric
Aβ treated cells, immunoﬂuorescent analysis of synaptophysin and
synaptotagmin showed a signiﬁcant increase in the number of positive
puncta after pre-treatment with antidepressants (Fig. 6A–C). Pre-
treatment with Imipramine or Escitalopram was able to reduce the
number of synaptic protein aggregations in CORT-treated neurons
(Fig. 6D–F).
4. Discussions
Depression andAD share common pathophysiological characteristics
including synaptic degeneration [43]. Synaptic degeneration is reﬂected
by pathological changes within the molecular components of pre- and
post-synaptic compartments [20]. Our results showed damages in the
pre-synaptic compartment, which was found to affect the recycling of
synaptic vesicles and ultimately the function of the synapse. Next,
we found that ubiquitin-mediated protein degradation mechanisms
appeared to be responsible for the clearance of aggregated synaptic
proteins, which may mediate the degenerative processes. Furthermore,
we found that antidepressants were able to alleviate the observed pre-
synaptic damage.
4.1. Synaptic damage
Our results showed that the pre-synaptic compartment was dam-
aged after treatmentwith oligomeric Aβ and CORT. Pre-synaptic protein
aggregation was observed after 12 h of treatment with Aβ, and protein
losswas observed at 24 h (Fig. 1). Although these changeswere present,
the dosage used did not signiﬁcantly affect cell viability or induce apo-
ptosis (Supplementary Figs. 1 & 2).With CORT, pre-synaptic protein ag-
gregation but not protein loss was observed 24 h after treatment
(Fig. 2). These observations suggest that pre-synaptic proteins undergo
aggregation, followed by loss of proteins. Since there was no signiﬁcant
change in PSD95 following treatmentwith Aβ and CORT (Supplementa-
ry Figs. 3 & 4), it appeared that pre-synaptic damage occurred before
post-synaptic damage. There is a possibility that PSD95 could be affect-
ed after 24 h; however, longer treatment durationswere not investigat-
ed. Despite the temporal differences in the occurrence of the synaptic
pathologies, the pre-synaptic damage induced by CORT resembled
that induced by oligomeric Aβ.
Our next question was whether the observed morphological
changes would affect synaptic functions. Synaptic vesicles undergo traf-
ﬁcking, docking, fusion to the synaptic membrane, and ultimately the
release of neurotransmitters. After neurotransmitter release, empty
synaptic vesicles either recycle back to the releasable pool or fuse with
the endosome where mature vesicles subsequently bud off [44]. The
FM®4-64 ﬂuorescent probe is commonly used to label synaptic vesicles
for live-cell imaging of synaptic function [45]. Upon neuronal stimula-
tion, the synaptic vesicles will release the dye through exocytosis. The
decrease in dye intensity over a period of time indicates the rate of
exocytosis. Our results showed that after treatment with oligomeric
Aβ and CORT, dye exocytosis was slower (Fig. 3). These results indicate
that the observed pathological changes affect synaptic functions by
delaying exocytosis and perhaps the release of neurotransmitters.Fig. 1. Low-dose oligomeric Aβ induced aggregation of pre-synaptic proteins at 12 h and loss of p
in the number of immunoreactive puncta of synaptophysin and synaptotagminwhile aggregatio
pocampal neurons transducedwith CellLight® synaptophysin-GFP also showed reduction in imm
E, F, G) Quantitative analysis of the number of puncta and aggregations was performed by Mac
pendent experiments. Statistical analysis was performed by unpaired t-test. * represents p b 0
teins showed reduced protein levels. I) Quantitative Western blot analysis by MacBiophoton
experiments. Statistical analysis was performed by one-way ANOVA, followed by post hoc Tuk4.2. Protein degradation and the synapse
To further elucidate the mechanisms underlying the synaptic
protein damages, protein degradation mechanisms were investigated.
The major cellular protein degradation pathways are the ubiquitin–
proteasome system and the autophagy–lysosomal pathway. Ubiquitin
appears to be a common denominator in targeting unwanted proteins
for degradation by both pathways. Also, ubiquitinated proteins are
consistently present in protein aggregates found in many neurodegen-
erative diseases [46].
Ubiquitination involves a cascade of enzymes including ubiquitin-
activating enzymes (E1), conjugating enzymes (E2), and ligases (E3)
[47]. E1 binds to ubiquitin and ATP to form a complex. Ubiquitin
is then passed on to E2. Ubiquitin-charged E2 then forms a complex
with an E3 ligase and a protein substrate. Ubiquitin is then transferred
onto the protein substrate. Studies have shown that if the protein
substrate is linked to the lysine 48 residue of ubiquitin, the substrate
is signaled for degradation by the proteasome. On the other hand, if
the polyubiquitin chain is formed by the linkage of the substrate to
the lysine 63 residue, the substrate is preferentially degraded by the
lysosome [48].
Our results showed that therewas an increase in ubiquitin-48 and -63
immunoreactivities in both Aβ and CORT treated groups (Fig. 4). At the
synaptic level, our ﬁndings support previous studies that investigate the
crucial involvement of protein degradation mechanisms in maintaining
proper synaptic functions. Ubiquitin has been known to function locally
at the synapse [49] and several ubiquitin related enzymes have been
found to regulate synaptic functions [50]. Furthermore, several synaptic
proteins are substrates for ubiquitin, including synaptophysin [51].
Our results also showed that ubiquitin-63 signiﬁcantly co-localized
with synaptophysin for both treatment groups, while ubiquitin-48
did not (Fig. 4). Pathological accumulation of autophagic vacuoles has
been observed in AD brains [52,53]. Up-regulation of the autophagy–
lysosomal degradation pathway has been shown to increase production
and accumulation of intracellular Aβ [54]. Our observations suggest that
up-regulation of this degradation pathway is also associated with CORT
induced toxicity, providing another evidence for the similarities be-
tween depression and AD.
Higher levels of co-localization between ubiquitin-63 and
synaptophysin after treatment with Aβ and CORT would suggest
increased activation of ubiquitin-mediated protein degradation that
preferentially signals for autophagy–lysosomal degradation pathway.
Treatment with CORT or Aβ did not induce changes in any of the three
proteolytic activities of the proteasome (Fig. 5), supporting the notion
that following treatment, the autophagy–lysosomal pathway may play
amore prominent role compared to the ubiquitin–proteasomepathway.
To further elucidate the activation of the autophagic pathway, we
performed immunocytochemical analysis for LC3-II, which is amark-
er for autophagosomes [55] (Supplementary Fig. 5). LC3-II is a pro-
tein located in the inner and outer membrane of autophagosomes.
Ubiquitinated proteins at lysine 63 recruit the LC3-interacting protein
p62. p62 is then recognized by LC3-II. Protein substrate tagged with
ubiquitin-63, p62 and LC3-II forms a complex which is then engulfed
by the autophagosome, and subsequently degraded by the lysosomes
[56]. In accordance with the increased immunoreactivity of ubiquitin-
63 in Aβ and CORT treated cells, there was also an increase in the num-
ber of LC3-II puncta following treatment. Therefore, in our study, were-synaptic proteins at 24 h. A&D) Treatmentwith 0.5 μMAβ for 24 h caused a reduction
ns of these proteinswere observed after 12 h treatment. Live-cell imaging of primary hip-
unoreactive positive puncta. Imageswere taken at a 63× objective (scale bar 10 μm). B, C,
Biophotonics ImageJ. Results were expressed as fold of control ± SE from at least 3 inde-
.05 compared to the corresponding control. H) Western-blot analysis of pre-synaptic pro-
ics Image J. Results were expressed as fold of control ± SE from at least 3 independent
ey's test. * represents p b 0.05 compared to the corresponding control.
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cytosiswhen thedyewas supposed to be released (and the subsequent decrease inﬂuorescent intensity), C)ﬂuorescent intensity of the treatedneurons remained at an elevated level. This
indicates that the ﬂuorescent probe was not being properly released; hence exocytosis appeared to be slower in treated neurons. Results were expressed as fold of control ± SE from at
least 3 independent experiments. Statistical analysiswas performed by unpaired t-test. * & ** represent p b 0.05 andp b 0.01 compared to the corresponding control. Imageswere taken at
a 63× objective (3× digital zoom; scale bar 10 μm).
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autophagy–lysosomal degradation pathway induced by either CORT or
Aβ, which may contribute to the pathological changes in pre-synaptic
proteins and its functions.
The role of protein degradation at the synapse is to maintain its
plasticity; however, the imbalance in the degradation process may
disturb synaptic functions [57]. Protein degradation mechanisms are
important in maintaining proper synaptic function and its dysfunction
could have detrimental results in the synapse. Although the involve-
ment of ubiquitinated proteins and autophagy has been widely investi-
gated in AD pathology, it is not well studied in depression. This study
suggests the possible importance of its role in the pathology of depres-
sion. Sincemodulation of the autophagy–lysosomal protein degradation
pathway has been shown to lead to numerous neurodegenerative
diseases, its involvement in depression provides new insight as to
why depressed patients may develop neurodegenerative diseases such
as AD later on in life.4.3. Antidepressants are able to alleviate pre-synaptic protein damages
According to our ﬁndings, synaptic degeneration may be an up-
stream pathological process in depression in AD. Our results demon-
strated that the selected antidepressants were able to alleviate the
observed synaptic damage. The use of various antidepressants has long
been used in treating depressive disorders [58]. Several classes of anti-
depressants are available, including tricyclic antidepressants (TCAs)
and the selective serotonin reuptake inhibitors (SSRIs) [59,60]. Several
studies have shown that SSRIs are able to improve cognition anddepres-
sive symptoms in both animal models and AD patients [5,61,62]. How-
ever, a recent clinical trial of the SSRI sertraline, and the noradrenergic
and speciﬁc serotonergic antidepressant mirtazapine failed to show
any effects over placebo in the treatment of depression in AD patients
[63].
We selected one of the “classical” TCAs imipramine and the
newer SSRIs escitalopram for our study to investigate whether
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Fig. 5. Low-dose oligomeric Aβ and CORT did not mediate changes in proteasome activity. Primary hippocampal neurons were treated with 0.5 μM Aβ and CORT and analyzed for
proteasome activity using a ﬂuorescence activity assay. No signiﬁcant changes in the chymotrypsin-like, trypsin-like, and caspase-like activities of the proteasome were found after
treatment with low dose oligomeric Aβ and CORT. Results were expressed as fold of control ± SE from 4 independent experiments. Statistical analysis was performed by one-way
ANOVA followed by post hoc Tukey's test.
2253S. Wuwongse et al. / Biochimica et Biophysica Acta 1832 (2013) 2245–2256these antidepressants would be able to protect neurons from the toxic
effects induced by Aβ and CORT. Our study showed that both antide-
pressants could attenuate the loss or aggregation of synaptic proteins
(Fig. 6). Interestingly, imipramine and escitalopram are two different
classes of antidepressants, with imipramine being non-speciﬁc, while
escitalopram being highly speciﬁc to the serotonergic system. This sug-
gests that the modulation of serotonin uptake transporters may not be
the only underlyingmechanism involved. It would be interesting to fur-
ther investigate other possible underlying pathways of how antidepres-
sant affects synaptic proteins.
It is important to note that the pathogenesis of depression and AD
does not only involve synaptic degeneration. Although the present
study has shown that synaptic degeneration and ubiquitin-mediated
protein degradation mechanisms are involved in depression and AD,
other factors including neuroinﬂammation, oxidative stress, and neuro-
transmitter dysregulation cannot be excluded. Sincewe have utilized an
in vitro disease model for this study, we were only able to investigate
the effects of CORT as a model for depression and oligomeric Aβ as a
model for AD. Other factors involved in each disorder were not investi-
gated including monoamine deﬁciency for depression and NFT for AD.
Depression appears to share similar neurodegenerative processes as
AD.Wehave provided signiﬁcant evidence to show that synaptic degen-
eration is a commonpathological feature of both depression andAD. The
observed synaptic protein loss and aggregation appeared to be associat-
ed with the ubiquitin-mediated autophagy–lysosomal pathway. Since
the involvement of this pathway is not well studied in depression, our
study provides new insight into the pathology of depression and further
supports the idea that similarmolecular neuropathology exists between
depression and AD. Moreover, our observation that antidepressants
were able to alleviate the synaptic pathologies, implicates that theFig. 4. Low-dose oligomeric Aβ and CORT induced ubiquitin-mediated protein degradation
ubiquitin-48 immunoreactivity. Increase in the number of positive ubiquitin-48 puncta and
10 μMserved as a positive control. B) Quantiﬁcation of the immunoreactivity was performed by
ment. Results were expressed as fold of control ± SE from at least 3 independent experiments
*, **, & *** represent p b 0.05, p b 0.01, and p b 0.001compared to the corresponding control. C
localization level in the treated group, except in the lactacystin treated neurons. Statistical ana
p b 0.05 compared to the corresponding control. D) Primary hippocampal neurons were exa
ubiquitin-63 puncta and co-localization with synaptophysin (indicated by arrows) was observ
reactivity was performed byMacBiophotonics ImageJ. There was a signiﬁcant increase in numb
independent experiments. Statistical analysiswas performed by one-way ANOVA, followed by p
corresponding control. F) Manders' coefﬁcient for co-localization analysis showed a signiﬁcant i
Statistical analysiswas performed by one-way ANOVA, followed by post hoc Tukey's test. *, **, &
ing control. Images were taken at a 63× objective (3× digital zoom; scale bar 10 μm).prevention of synaptic degeneration may be pivotal in the early thera-
peutic intervention of these two disorders and further investigations
are highly warranted.
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